These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21406038)

  • 1. Novel calcium sensing receptor ligands: a patent survey.
    Kiefer L; Leiris S; Dodd RH
    Expert Opin Ther Pat; 2011 May; 21(5):681-98. PubMed ID: 21406038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures.
    Nemeth EF; Goodman WG
    Calcif Tissue Int; 2016 Apr; 98(4):341-58. PubMed ID: 26319799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders.
    Nemeth EF; Shoback D
    Best Pract Res Clin Endocrinol Metab; 2013 Jun; 27(3):373-84. PubMed ID: 23856266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcimimetics and calcilytics--fooling the calcium receptor.
    Steddon SJ; Cunningham J
    Lancet; 2005 Jun 25-Jul 1; 365(9478):2237-9. PubMed ID: 15978932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical use of calcimimetics in the treatment of hyperparathyroidisms].
    Urena P
    Med Sci (Paris); 2004 Nov; 20(11):973-8. PubMed ID: 15525492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosteric modulators of the extracellular calcium receptor.
    Nemeth EF
    Drug Discov Today Technol; 2013; 10(2):e277-84. PubMed ID: 24050279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights into the role of calcium-sensing receptor activation.
    Cozzolino M; Mazzaferro S; Messa P
    J Nephrol; 2011; 24 Suppl 18():S38-41. PubMed ID: 21623581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Calcimimetics].
    Messa P; Como G; Brezzi B
    G Ital Nefrol; 2006; 23(1):12-21. PubMed ID: 16521071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcilytics: antagonists of the calcium-sensing receptor for the treatment of osteoporosis.
    Widler L
    Future Med Chem; 2011 Apr; 3(5):535-47. PubMed ID: 21526895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet.
    de Francisco AL; Izquierdo M; Cunningham J; Piñera C; Palomar R; Fresnedo GF; Amado JA; Unzueta MG; Arias M
    Nephrol Dial Transplant; 2008 Sep; 23(9):2895-901. PubMed ID: 18424820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent updates on the calcium-sensing receptor as a drug target.
    Trivedi R; Mithal A; Chattopadhyay N
    Curr Med Chem; 2008; 15(2):178-86. PubMed ID: 18220773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Calcimimmetic and calcilytics: new perspectives of correction of abnormal parathormone (PTH) secretion].
    Rybczyńska A; Hoppe A
    Przegl Lek; 2003; 60(6):418-24. PubMed ID: 14974181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic use of calcimimetics.
    Hebert SC
    Annu Rev Med; 2006; 57():349-64. PubMed ID: 16409154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological regulation of parathyroid hormone secretion.
    Nemeth EF
    Curr Pharm Des; 2002; 8(23):2077-87. PubMed ID: 12171519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Achieving therapeutic targets in the treatment of secondary hyperparathyroidism.
    Cunningham J
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V9-14. PubMed ID: 15284354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives.
    Drüeke TB; Ritz E
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):234-41. PubMed ID: 19056615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcimimetic and calcilytic drugs: just for parathyroid cells?
    Nemeth EF
    Cell Calcium; 2004 Mar; 35(3):283-9. PubMed ID: 15200152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Summary--calcium receptors: potential targets for novel treatments for skeletal disease.
    Nemeth EF
    J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):416-7. PubMed ID: 15758288
    [No Abstract]   [Full Text] [Related]  

  • 20. A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo.
    Arey BJ; Seethala R; Ma Z; Fura A; Morin J; Swartz J; Vyas V; Yang W; Dickson JK; Feyen JH
    Endocrinology; 2005 Apr; 146(4):2015-22. PubMed ID: 15637285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.